Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Vivo Capital

Latest statistics and disclosures from Vivo Capital's latest quarterly 13F-HR filing:

Top 5 stock holdings are ERAS, PRAX, TERN, TRVI, DBVT, and represent 40.95% of Vivo Capital's stock portfolio.
Added to shares of these 10 stocks: ERAS (+$47M), SNSE (+$23M), AVBP (+$20M), Veradermics (+$19M), ANTX (+$11M), CRVS (+$8.4M), OKUR (+$8.0M), ALXO (+$6.4M), Satellos Bioscience, DBVT.
Started 8 new stock positions in Satellos Bioscience, ANTX, AVBP, OKUR, SNSE, Veradermics, ALXO, CMPS.
Reduced shares in these 10 stocks: TERN (-$212M), CDTX (-$211M), COGT (-$76M), AVDL (-$58M), ZBIO (-$31M), GERN (-$28M), SLNO (-$20M), DYN (-$19M), VRDN (-$16M), ABVX (-$13M).
Sold out of its positions in ABEO, CDTX, CTMX, ENGNW, PALI, SLN, VSTM, ZBIO, AVDL.
Vivo Capital was a net seller of stock by $-580M.
Vivo Capital has $1.2B in assets under management (AUM), dropping by -22.24%.
Central Index Key (CIK): 0001674712

Tip: Access up to 7 years of quarterly data

Positions held by Vivo Capital consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Vivo Capital

Vivo Capital holds 46 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Erasca Common (ERAS)	16.3	$197M	+31%	12M	16.18	View chart
Praxis Precision Medicines Common (PRAX)	9.1	$109M	+3%	339k	322.19	View chart
Terns Pharmaceuticals Common (TERN)	5.8	$70M	-75%	1.3M	52.72	View chart
Trevi Therapeutics Common (TRVI)	5.1	$61M		5.1M	11.93	View chart
DBV Technologies SA Sponsored Ads (DBVT)	4.6	$56M	+8%	2.7M	20.89	View chart
Compass Therapeutics Common (CMPX)	4.2	$51M		9.5M	5.29	View chart
Tango Therapeutics Common (TNGX)	3.7	$45M		2.2M	20.92	View chart
SAB Biotherapeutics Common (SABS)	3.6	$44M		11M	3.83	View chart
Corvus Pharmaceuticals Holdings Common (CRVS)	3.4	$41M	+25%	2.8M	14.63	View chart
Bright Minds Biosciences Common (DRUG)	3.4	$41M	+11%	557k	72.97	View chart
Sinovac Biotech SHS	3.2	$38M		5.9M	6.47	View chart
Dianthus Therapeutics Common (DNTH)	2.5	$30M		354k	83.92	View chart
Dyne Therapeutics Common (DYN)	2.3	$28M	-40%	1.6M	18.13	View chart
Abivax SA - Sponsored Ads (ABVX)	2.2	$27M	-33%	240k	111.35	View chart
Minerva Neurosciences Common (NERV)	2.2	$26M		4.3M	6.03	View chart
Aclaris Therapeutics Common (ACRS)	2.1	$25M	-25%	6.7M	3.75	View chart
Oric Pharmaceuticals Common (ORIC)	1.9	$23M	-12%	1.8M	12.67	View chart
Alto Neuroscience Common (ANRO)	1.9	$23M		1.0M	22.48	View chart
Sensei Biotherapeutics Common (SNSE)	1.9	$23M	NEW	722k	31.52	View chart
Arrivent BioPharma Common (AVBP)	1.7	$20M	NEW	886k	23.07	View chart
LB Pharmaceuticals Common (LBRX)	1.6	$20M		800k	24.66	View chart
Veradermics Common	1.6	$19M	NEW	300k	63.15	View chart
CAMP4 Therapeutics Common (CAMP)	1.6	$19M		4.2M	4.41	View chart
Moonlake Immunotherapeutics Common (MLTX)	1.5	$19M		1.0M	18.64	View chart
Design Therapeutics Common (DSGN)	1.4	$17M		1.6M	10.64	View chart
Cogent Biosciences Common (COGT)	1.4	$16M	-82%	422k	38.49	View chart
Geron Corp Common (GERN)	1.1	$13M	-68%	8.7M	1.49	View chart
Unicycive Therapeutics Common (UNCY)	1.0	$12M		1.8M	6.58	View chart
AN2 Therapeutics Common (ANTX)	0.9	$11M	NEW	3.2M	3.42	View chart
Olema Pharmaceuticals Common (OLMA)	0.8	$10M		672k	14.91	View chart
Soleno Therapeutics Common (SLNO)	0.8	$9.9M	-67%	295k	33.48	View chart
Eupraxia Pharmaceuticals Common (EPRX)	0.8	$9.8M		1.4M	7.24	View chart
Onkure Therapeutics Common (OKUR)	0.7	$8.0M	NEW	1.9M	4.14	View chart
Surrozen Common (SRZN)	0.6	$7.6M		260k	29.13	View chart
ALX Oncology Holdings Common (ALXO)	0.5	$6.4M	NEW	3.2M	2.00	View chart
Monopar Therapeutics Common (MNPR)	0.4	$5.0M		91k	54.79	View chart
Satellos Bioscience Common	0.4	$4.6M	NEW	814k	5.63	View chart
Pepgen Common (PEPG)	0.3	$4.1M		2.3M	1.77	View chart
Sera Prognostics Common (SERA)	0.3	$3.4M		1.7M	2.03	View chart
Tenax Therapeutics Common (TENX)	0.3	$3.3M		208k	15.99	View chart
Viridian Therapeutics Common (VRDN)	0.3	$3.3M	-83%	166k	19.56	View chart
Instil Bio Common (TIL)	0.2	$2.4M		293k	8.24	View chart
Pasithea Therapeutics Corp Common (KTTA)	0.1	$1.6M		2.1M	0.74	View chart
Compass Pathway Sponsored Ads (CMPS)	0.1	$1.1M	NEW	200k	5.53	View chart
Bolt Therapeutics Common (BOLT)	0.0	$293k		72k	4.04	View chart
Precision Biosciences Common (DTIL)	0.0	$26k		4.7k	5.50	View chart

Past Filings by Vivo Capital

SEC 13F filings are viewable for Vivo Capital going back to 2016

Vivo Capital 2026 Q1 restated filed May 20, 2026
Vivo Capital 2026 Q1 filed May 15, 2026
Vivo Capital 2025 Q4 filed Feb. 13, 2026
Vivo Capital 2025 Q3 filed Nov. 14, 2025
Vivo Capital 2025 Q2 filed Aug. 14, 2025
Vivo Capital 2025 Q1 filed May 12, 2025
Vivo Capital 2024 Q4 filed Feb. 13, 2025
Vivo Capital 2024 Q3 filed Nov. 13, 2024
Vivo Capital 2024 Q2 filed Aug. 14, 2024
Vivo Capital 2024 Q1 filed April 22, 2024
Vivo Capital 2023 Q4 filed Feb. 7, 2024
Vivo Capital 2023 Q3 filed Nov. 8, 2023
Vivo Capital 2023 Q2 filed Aug. 14, 2023
Vivo Capital 2023 Q1 filed May 15, 2023
Vivo Capital 2022 Q4 filed Feb. 13, 2023
Vivo Capital 2022 Q3 filed Nov. 14, 2022

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z